Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Clinical trial NCT06770582 · RECRUITING

Trial details

NCT number: NCT06770582
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Muscle Invasive Bladder Urothelial Carcinoma Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma Stage I Bladder Cancer AJCC v8

Start date: 2025-06-03
Primary completion: 2032-02-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.